Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Summary

This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.

Timeline

Start

2024-03-25

Primary completion

2026-03-25

Completion

2026-06-25

Drugs

Indications